Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Lancet Oncol. 2020 Mar 17;21(4):541–550. doi: 10.1016/S1470-2045(20)30023-1

Table 4.

PD-L1 expression on tumor cells and infiltrating immune cells.

Histology Tumor PD-L1 testing Number of patients (%) PD-L1+tumor$ no. (%) Range of % PD-L1+positive tumor cells Tumors with Infiltrating Immune Cells no. (%) Predominant PD-L1+ Immune Cell
HL 9/12 (75) 9/9 (100) 30–100 9/9 (100) Macrophages
NHL 8/10 (80) 7/8 (88) 1–100 8/8 (100) Macrophages or Lymphocytes
NBL 15/22 (68) 1/15 (7) 1 14/15 (93) Macrophages or Lymphocytes
OS 9/13 (69) 2/9 (22) 1–3 7/9 (78) Macrophages or Lymphocytes
RMS 9/12 (75) 1/9 (11) 1 8/9 (89) Macrophages or Lymphocytes
ES 10/11 (91) 1/10 (10) 1 8/10 (80) Macrophages
Malignant melanoma 0/1 (0) - - - -
Other Sarcoma* 4/4 (100) 2/4 (50) 5–70 4/4 (100) Macrophages
$

positive tumors are those showing PD-L1 on ≥ 1% of tumor cells

*

Malignant spindle cell and epithelioid neoplasm with focally rhabdoid features (1), treated spindle and pleomorphic sarcoma (1), proximal type epithelial sarcoma (1), and metastatic epithelioid sarcoma (1).